✦ LIBER ✦

Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer

✍ Scribed by Guo Jian; Zhou Songwen; Zhang Ling; Deng Qinfang; Zhang Jie; Tang Liang; Zhou Caicun

Publisher: Springer-Verlag
Year: 2010
Tongue: English
Weight: 354 KB
Volume: 136
Category: Article
ISSN: 1432-1335
DOI: 10.1007/s00432-010-0785-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Detection of epidermal growth factor rec

Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer

✍ Chen He; Ming Liu; Chengzhi Zhou; Jiexia Zhang; Ming Ouyang; Nanshan Zhong; Jun 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 260 KB 👁 2 views

## Abstract The high frequency of epidermal growth factor receptor (__EGFR__) mutations in tyrosine kinase inhibitor‐responsive non‐small‐cell lung cancer (NSCLC) cases is now well established, highlighting the predictive value of activating __EGFR__ mutations in guiding the clinical use of __EGFR_

The different efficacy of gefitinib or e

The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients

✍ Jong-Mu Sun; Young-Woong Won; Seung Tae Kim; Jung Hoon Kim; Yoon-La Choi; Jeeyun 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 304 KB

Epidermal growth factor receptor mutatio

Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer

✍ Jin-Yuan Shih; Chien-Hung Gow; Chong-Jen Yu; Chih-Hsin Yang; Yih-Leong Chang; Me 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 161 KB 👁 2 views

## Abstract Recently, mutations in the __epidermal growth factor receptor__ (__EGFR__) gene in nonsmall cell lung cancer (NSCLC) patients were reported to correlate with gefitinib response. Less than 30% of NSCLC patients are surgically resectable; however, molecular analysis has to rely on nonsurg

Comparative analysis of epidermal growth

Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer

✍ Takashi Sone; Kazuo Kasahara; Hideharu Kimura; Kazuto Nishio; Masayuki Mizuguchi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 235 KB 👁 1 views

## Abstract ## BACKGROUND. Because the investigation of epidermal growth factor receptor gene (__EGFR__) status as a predictor of gefitinib efficacy in Japanese patients has shown promise, the authors evaluated __EGFR__ mutations and gene amplification in biopsy specimens from Japanese patients wi

Amplification and overexpression of the

Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer

✍ Peter T. Reissmann; Hironobu Koga; Robert A. Figlin; E. Carmack Holmes; Dennis J 📂 Article 📅 1999 🏛 Springer-Verlag 🌐 English ⚖ 342 KB

Epidermal growth factor receptor immunoh

Epidermal growth factor receptor immunohistochemistry : Comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer

✍ Fred R. Hirsch; Rafal Dziadziuszko; Nick Thatcher; Helen Mann; Claire Watkins; D 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 2 views

## Abstract ## BACKGROUND The ISEL (Iressa Survival Evaluation in Lung Cancer) clinical trial evaluated the efficacy of gefitinib versus placebo in pretreated nonsmall‐cell lung cancer patients. Two different antibodies, scoring systems, and cutoff points of epidermal growth factor receptor (EGFR)